Searched for
INSULIN ASPART
Kiran Mazumdar-Shaw names niece Claire as successor, targets semaglutide push from FY28; debt cut to $1.1 billionBiocon's Executive Chairperson, Kiran Mazumdar-Shaw, outlined a five-year leadership transition with her niece, Claire Mazumdar, as success...- CDSCO issues alert on Novo drugs after reported theftThe CDSCO has alerted healthcare professionals and consumers about stolen Novo Nordisk products, including semaglutide and insulin injectab...
- Biocon sees GLP-1 weight-loss therapy as a future growth driverBiocon will strengthen its insulin business while advancing in GLP-1 therapies, with semaglutide in Phase-III trials and a planned 2027 Ind...
- Biocon Biologics gets USFDA nod for diabetes medicationBiocon Biologics has secured USFDA approval for Kirsty. Kirsty is an interchangeable biosimilar to NovoLog, used for diabetes treatment. It...
- Biocon shares surge 3% as subsidiary obtains USFDA approval for diabetes drugBiocon share price jumped after its subsidiary Biocon Biologics received USFDA approval for Kirsty, a rapid-acting insulin biosimilar. This...
- Biocon shares climb 1% on partnership with Civica to boost insulin aspart availability in the USBiocon Biologics has partnered with Civica to improve access to and affordability of insulin aspart in the U.S. Biocon will supply the insu...
- Biocon Biologics' Malaysia insulin facility classified by US FDA for official actionBiocon Biologics has announced that its insulin manufacturing facility in Johor, Malaysia has been classified as an official action indicat...
- Govt grants sanction to prosecute joint drugs controller S Eswara Reddy in Biocon Biologics bribery caseEswara Reddy along with Animesh Kumar (Assistant Drugs Inspector), Biocon Biologics' Associate Vice President L Praveen Kumar, and Synergy ...
- Regulatory checks on pharmaceutical products stringent, say former CDSCO membersThe comments came after the Central Bureau of Investigation (CBI) recently arrested five people, including a senior CDSCO official, for all...
- CBI Probe: Biocon denies bribery charges, says it followed due process of lawThe Bengaluru-headquartered company, in a statement, said it is governed by a strong code of conduct and condemns any acts of corruption an...
- Biocon arm denies bribery charges, says cos follows code of conductThe guidelines provide a framework for waiver of phase III clinical trials in India based on a commitment to undertake a phase IV trial, th...
- Biocon Biologics denies bribery charge; says it follows due regulatory process for product approvalsThe CBI has arrested Joint Drugs Controller S Eswara Reddy, Associate Vice President of Biocon Biologics L Praveen Kumar and three others i...
- CBI apprehends joint drugs controller taking Rs 4 lakh bribe to clear Biocon subsidiary productIt was alleged that the accused was trying to exert undue influence on officers of CDSCO (Central Drugs Standard Control Organisation) unde...
- Biocon eyes $30b US insulin market via its biosimilarsWith the approval of aspart, Biocon says it will become the first company to receive approvals for two interchangeable insulin drugs in the...
- USFDA issues six observations after inspection of Biocon's Malaysian arm manufacturing facilityA Biocon spokesperson said the company is confident of addressing these observations through procedural enhancements and an appropriate Cor...
- Biocon, Mylan's diabetic drug receives positive opinion from European Medicines AgencyBiocon said the CHMP positive opinion will be considered by the European Commission. The European Commission decision on the approval is ex...
- Biocon partners with Voluntis to develop digital therapeutics for diabetes patientsThe licensing agreement, signed between Biocon Biologics’ subsidiary Biocon Sdn. Bhd., Malaysia and Voluntis, would make Biocon Biologics o...
- Biocon to further develop insulin TregopilBiocon CMD Kiran Mazumdar-Shaw said: "The data is extremely promising and based on what we know today Tregopil may be positioned as a uniqu...
- Pfizer deal shot in arm for BioconAs per the deal, Biocon will conduct clinical development and regulatory filings while Pfizer will get the exclusive rights to market these...
- Market gives thumbs up to Biocon's deal with PfizerThe Bangalore-based firm’s scrip opened at Rs 445, reached an intra-day high of Rs 464.6 before closing at Rs 455, up 12.97% over Monday’s ...
Load More
